• Union Korea Pharm filed a corrected 2026 first-half report dated Oct. 12, 2026, revising treasury share disclosures.
• Treasury shares held as of June 30, 2026 were restated to 227,777 common shares, equal to 0.03% of issued shares.
• It disclosed a May 27, 2026 capital reduction that cancelled 455,556 common shares, valued at KRW 227,778,000.
• The company said it has no confirmed short-term plans to buy, sell, or cancel additional treasury shares.
• It said amended Commercial Act rules require disposal or cancellation of all 227,777 shares by Sept. 5, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Union Korea Pharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012000157), on October 12, 2026, and is solely responsible for the information contained therein.